Navigation Links
Micromet Added to Russell 3000 Index
Date:6/29/2009

Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human antibody MT228 for the treatment of melanoma.

Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do n
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
2. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
3. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
4. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
5. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
6. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
7. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
8. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
9. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
10. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
11. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Md. , March 2, 2015 ... -based biotechnology company focusing on the research ... next generation antibody agents based upon a novel ... a 2015 Life Sciences Impact Grant Award from ... The grant, created by MCDED, is awarded to ...
(Date:3/2/2015)... NEW YORK , March 2, 2015 ... please scroll to bottom.   Moments ago, ... situations including Sunshine Heart (NASDAQ: SSH ... SURG ), Syneron Medical (NASDAQ: ELOS ), Spectranetics ... THOR ). Analysts Review provides a single unified platform for ...
(Date:3/2/2015)... March 02, 2015 Global ... formed alliance with Shenzhen HANK Bioengineering Co., Ltd. ... The alliance will establish a stem cells training ... China in September 2015. , Shenzhen HANK is ... an award-winning scientist, microbiologist and virologist, to integrate ...
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... been made aware of a fraudulent press release disseminated ... purporting to be from Immunovaccine. This press release states ... Gilead Science, Inc. The press release did not ... the information contained within the press release. Please ...
Breaking Biology Technology:VLP Therapeutics Wins the 2015 Life Sciences Impact Grant Award from the Montgomery County Department of Economic Development 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3Immunovaccine Disclaims Hoax Press Release 2
... know there are at least five different types of patent ... (1) a search for competitors patents, (2) a clearance search, ... a patent validity search. Each type of search has a ... for competitors patents ,A search for competitors patents is ...
... business. , ,I call it the "humanizing factor" at work. A ... corporate world and the behavior of people in it, but in ... regular people at work (sometimes when you least expect it). , ... examples of the HF in action. , ,A friend goes on ...
... at a Senate appearance earlier this year. Credit: U.S. ... and Human Services Secretary Tommy Thompson announced Wednesday the ... national health information infrastructure in 10 years and bring ... also released a report, prepared by National Health IT ...
Cached Biology Technology:Five ways your company can benefit from patent searches 2Five ways your company can benefit from patent searches 3'Don't work here' job interviews set new Midwest technology trend 2'Don't work here' job interviews set new Midwest technology trend 3'Don't work here' job interviews set new Midwest technology trend 4'Don't work here' job interviews set new Midwest technology trend 5Thompson announces 'Decade of Health Information Technology' 2Thompson announces 'Decade of Health Information Technology' 3Thompson announces 'Decade of Health Information Technology' 4Thompson announces 'Decade of Health Information Technology' 5Thompson announces 'Decade of Health Information Technology' 6
(Date:2/19/2015)... Feb .19, 2015 Research and Markets ... of the "Military Electro-Optical / Infrared Systems ... by Platform - Forecast to 2020" report ... electro-optical/infrared systems market is expected to reach $16.35 ... 7.71%. This report segments the military ...
(Date:2/13/2015)... Feb. 13, 2015 ACT Genomics Co., ... aims to transform cancer genomic information into precision ... company has raised US$ 8 million in the its ... Taipei, Taiwan , ACT Genomics ... With the aim to implement next generation sequencing ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62/113114 for DISTRIBUTED METHOD ... The patent further establishes NXT-ID,s position in ... intellectual property portfolio the ability for multiple devices to ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3
... and swift, viruses are hard to capture on video. Now ... a virus-like particle as it tries to break into and ... learn more about how to deliver drugs via nanoparticles ... well as how to prevent viral infection from occurring. ...
... a busy airport where cold viruses and other germs circulate ... bees and butterflies can pick up fungal, bacterial or viral ... as debilitating as influenza. But "almost nothing is ... postdoctoral researcher Scott McArt and Professor Lynn Adler at the ...
... Rett Syndrome Foundation (IRSF) announces today ten (10) new ... Translational Research Program; and additional funding for current human ... 2013 covers the spectrum of Rett syndrome research, from ... way to treating the girls diagnosed with Rett syndrome. ...
Cached Biology News:Now in 3-D: Video of virus-sized particle trying to enter cell 2Now in 3-D: Video of virus-sized particle trying to enter cell 3As hubs for bees and pollinators, flowers may be crucial in disease transmission 2IRSF announces 2013 awards and implements new Translational Program 2IRSF announces 2013 awards and implements new Translational Program 3
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
... monitoring Aldolase tests. 2 levels of ... manufacturing values at 4 ± 2 ... 30-day shelf life once opened ... 1: 3 x 3 ml; Level ...
Human VEGF-D Biotinylated MAb (Clone 78923)...
Mouse Wnt-11 Affinity Purified Polyclonal Ab...
Biology Products: